Does GLIVEC Cause Malignant neoplasm progression? 60 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 60 reports of Malignant neoplasm progression have been filed in association with GLIVEC. This represents 6.0% of all adverse event reports for GLIVEC.
60
Reports of Malignant neoplasm progression with GLIVEC
6.0%
of all GLIVEC reports
53
Deaths
12
Hospitalizations
How Dangerous Is Malignant neoplasm progression From GLIVEC?
Of the 60 reports, 53 (88.3%) resulted in death, 12 (20.0%) required hospitalization, and 1 (1.7%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for GLIVEC. However, 60 reports have been filed with the FAERS database.
What Other Side Effects Does GLIVEC Cause?
Death (628)
Gastrointestinal stromal tumour (40)
Chronic myeloid leukaemia (38)
Anaemia (30)
Second primary malignancy (27)
Pyrexia (21)
Blast crisis in myelogenous leukaemia (20)
Dyspnoea (19)
Malaise (16)
Thrombocytopenia (16)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which GLIVEC Alternatives Have Lower Malignant neoplasm progression Risk?
GLIVEC vs GLOFITAMAB
GLIVEC vs GLOFITAMAB-GXBM
GLIVEC vs GLUCAGON
GLIVEC vs GLUCAGON\GLUCAGON\WATER
GLIVEC vs GLUCARPIDASE